Stock Analysis

Ion Beam Applications Full Year 2023 Earnings: Beats Expectations

Simply Wall St

April 29, 2024

Ion Beam Applications (EBR:IBAB) Full Year 2023 Results

Key Financial Results

Revenue: €428.7m (up 19% from FY 2022).
Net loss: €9.11m (down by 250% from €6.06m profit in FY 2022).
€0.31 loss per share (down from €0.21 profit in FY 2022).

revenue-and-expenses-breakdown — ENXTBR:IBAB Revenue and Expenses Breakdown April 29th 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Ion Beam Applications Revenues and Earnings Beat Expectations

Revenue exceeded analyst estimates by 1.4%. Earnings per share (EPS) also surpassed analyst estimates by 37%.

The primary driver behind last 12 months revenue was the Proton Therapy and Other Accelerators segment contributing a total revenue of €366.4m (85% of total revenue). Notably, cost of sales worth €294.3m amounted to 69% of total revenue thereby underscoring the impact on earnings. The largest operating expense was General & Administrative costs, amounting to €53.8m (37% of total expenses). Explore how IBAB's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 7.0% growth forecast for the Medical Equipment industry in Europe.

Performance of the market in Belgium.

The company's shares are down 2.4% from a week ago.

Risk Analysis

Don't forget that there may still be risks. For instance, we've identified 1 warning sign for Ion Beam Applications that you should be aware of.

Valuation is complex, but we're helping make it simple.

Find out whether Ion Beam Applications is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.

View the Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.